Literature DB >> 18622235

Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families.

Norlela Sukor1, Paolo Mulatero, Richard D Gordon, Albertina So, David Duffy, Chiara Bertello, Livia Kelemen, Yvette Jeske, Franco Veglio, Michael Stowasser.   

Abstract

BACKGROUND: Familial hyperaldosteronism type II is a hereditary form of primary aldosteronism not attributable to the hybrid CYP11B1/CYP11B2 mutation that causes glucocorticoid remediable aldosteronism (or familial hyperaldosteronism type I). Although genetic defect(s) underlying familial hyperaldosteronism type II have not yet been elucidated, linkage to chromosome 7p22 was previously reported in two Australian families and a South American family with familial hyperaldosteronism type II.
OBJECTIVE: To seek evidence of linkage to chromosome 7p22 in two Italian families with familial hyperaldosteronism type II based on markers that have already yielded evidence of linkage in one South American and two Australian familial hyperaldosteronism type II families and to assess the combined multipoint logarithm of odds score in these five families (two Australian, two Italian, and one South American).
METHODS: Primary aldosteronism was diagnosed or excluded using widely accepted clinical and biochemical criteria. Genotypes of affected and unaffected Italian patients from two families were analysed using seven closely spaced microsatellite markers at 7p22, and multipoint logarithm of odds scores were calculated to assess linkage with familial hyperaldosteronism type II.
RESULTS: All known affected individuals (four and two, respectively) from each of two Italian families shared identical haplotypes for the seven markers, consistent with linkage of the disease locus with the 7p22 region. The combined multipoint logarithm of odds score for five families showing linkage at 7p22 was highly significant at 5.22 (theta = 0) for markers D7S462 and D7S517.
CONCLUSION: Linkage in two Italian families makes this the third geographical area to show linkage of familial hyperaldosteronism type II at 7p22, emphasizing the likely importance of this locus in identifying the causative mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622235     DOI: 10.1097/HJH.0b013e3283028352

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  21 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

2.  Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.

Authors:  Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

Review 3.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 4.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

5.  A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Authors:  Evangelia Charmandari; Amalia Sertedaki; Tomoshige Kino; Christina Merakou; Dax A Hoffman; Michael M Hatch; Darrell E Hurt; Lin Lin; Paraskevi Xekouki; Constantine A Stratakis; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

Review 6.  Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

Authors:  Michael Stowasser; Martin Wolley; Aihua Wu; Richard D Gordon; Julia Schewe; Gabriel Stölting; Ute I Scholl
Journal:  Curr Hypertens Rep       Date:  2019-04-04       Impact factor: 5.369

Review 7.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

Review 8.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 9.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

10.  Physiologic tailoring of treatment in resistant hypertension.

Authors:  J David Spence
Journal:  Curr Cardiol Rev       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.